Novavax announces data from phase I of Phase I/II placebo-controlled trial of COVID-19 vaccine (NVX-CoV2373) with and without Matrix-M adjuvant

The trial was conducted in healthy adults 18 to 59 years of age and all who received the vaccine developed IgG antibodies against the spike protein after a single dose, with many developing wild-type virus neutralising antibody responses, and 100% of them after second dose.

SPS commentary:

The company used its recombinant nanoparticle technology to create antigen derived from the virus’s spike (S) protein. It also contains the company’s saponin-based Matrix-M adjuvant to improve the immune response and stimulate high levels of neutralizing antibodies.

Biospace Inc.